Ulcerative colitis market to hit $4.2 billion by 2023

The ulcerative colitis market is set to grow from $2.7 billion in 2013 to $4.2 billion in 2023 in the USA, France, Germany, Italy, Spain, the UK and Japan, according to research by industry analysts Decision Resources Group.

The primary drivers in this period are expected to be the expanded use of tumor necrosis factor-alpha inhibitors for maintenance and uptake of emerging therapies as alternatives for the anti-TNFs. Decision Resources Group predicts that sales of biologics will contribute around $2.3 billion to the market in 2023.

The company’s ulcerative colitis report forecasts that conventional therapies such as aminosalicylates and corticosteroids will remain the standard first-line therapies for most ulcerative colitis patients, followed by immunosuppressants and/or biologics as second- and third- line treatments.